8-K: PDS Biotech Announces Clinical Program Updates and Third Quarter 2024 Financial Results

PDS Biotechnology Corporation provided a business update, reported its third quarter 2024 financial results, and announced modifications to its Phase 3 trial design for its lead candidate, Versamune HPV.

Summary

• PDS Biotechnology reported a net loss of approximately $10.7 million for the third quarter of 2024, slightly improved from a $10.8 million loss in the same period of 2023.
• The company's research and development expenses increased to $6.8 million, while general and administrative expenses decreased to $3.4 million.
• Total operating expenses decreased to $10.2 million for the quarter, compared to $10.5 million in the prior year.
• Cash and cash equivalents totaled approximately $49.8 million as of September 30, 2024.
• The company has updated the design of its VERSATILE-003 Phase 3 trial to reduce costs and time, with an expected FDA clearance decision by mid-December 2024 and site activation in the first quarter of 2025.
• The updated trial will include approximately 350 patients and maintains a 2:1 randomization with median overall survival as the primary endpoint.
• Data from the IMMUNOCERV Phase 2 trial showed promising clinical activity and a compelling safety profile for Versamune HPV in treating locally advanced cervical cancer.
• The company is exploring the next steps in the development of Versamune HPV for cervical cancer.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical trial updates and financial results, with a clear path forward for the company's lead program. The modifications to the Phase 3 trial design and promising data from other trials are encouraging, but the company's reliance on future financing and the inherent risks of clinical development temper the overall sentiment.

Positives

• The company's net loss decreased slightly compared to the same quarter last year.
• The company has a substantial cash balance of approximately $49.8 million.
• Modifications to the VERSATILE-003 trial design are expected to reduce costs and time to completion.
• The IMMUNOCERV Phase 2 trial showed promising results for Versamune HPV in cervical cancer.
• The VERSATILE-002 Phase 2 trial demonstrated a median overall survival of 30 months, indicating a potential survival benefit.
• The company has submitted an amended IND application to the FDA for the VERSATILE-003 trial.

Negatives

• The company reported a net loss of approximately $10.7 million for the third quarter of 2024.
• Research and development expenses increased to approximately $6.8 million for the quarter.
• Net interest expenses increased to approximately $0.5 million for the quarter.

Risks

• The company's ability to protect its intellectual property rights is a risk.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.
• The company has a limited operating history in its current line of business, making it difficult to evaluate its prospects.
• The timing and success of planned clinical trials are subject to risks and uncertainties.
• The company's ability to continue as a going concern is a risk factor.
• The company's future success depends on the successful implementation of its research and development programs and collaborations.

Future Outlook

The company plans to initiate the VERSATILE-003 Phase 3 trial in the first quarter of 2025, and is exploring the next steps in the development of Versamune HPV for cervical cancer. The company also anticipates multiple data readouts from NCI Phase 2 studies of PDS01ADC.

Management Comments

• Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, stated that the company has been actively engaged with investors and clinicians to discuss their strategy and funding requirements for the VERSATILE-003 Phase 3 trial.
• Dr. Bedu-Addo noted that minor modifications were made to the VERSATILE-003 trial design based on investor feedback and discussions with key opinion leaders to reduce the overall cost and time required to achieve an interim data readout and trial completion.
• Dr. Bedu-Addo concluded that the company is exploring the next steps in the development of Versamune HPV for cervical cancer.

Industry Context

PDS Biotech is operating in the competitive immunotherapy space, focusing on targeted treatments for HPV-related cancers. The company's approach of combining Versamune HPV with checkpoint inhibitors aligns with current trends in cancer treatment. The modifications to the Phase 3 trial design reflect a strategic response to investor feedback and the need for cost-effective clinical development.

Comparison to Industry Standards

• The reported median overall survival of 30 months in the VERSATILE-002 trial is promising when compared to the standard of care for recurrent/metastatic HNSCC, which typically shows median overall survival in the range of 10-13 months with treatments like pembrolizumab alone or in combination with chemotherapy.
• The objective response rate (ORR) of 36% in the VERSATILE-002 trial for patients with a CPS score of 1 is comparable to or better than the ORR of 19% reported for pembrolizumab alone in the KEYNOTE-048 study for similar patient populations.
• The disease control rate (DCR) of 77.4% in the VERSATILE-002 trial is also notable, as it indicates a significant proportion of patients experiencing either tumor shrinkage or stable disease, which is a key factor in evaluating the effectiveness of cancer treatments.
• The safety profile of Versamune HPV plus pembrolizumab appears to be favorable, with only 9% of patients experiencing Grade 3 treatment-related adverse events and 1% experiencing Grade 4 events, which is lower than the toxicity rates associated with chemotherapy-based regimens.
• The company's focus on HPV16-positive HNSCC aligns with the growing recognition of this as a distinct and rapidly growing type of cancer, and the company's approach of targeting the HPV16 E6 and E7 oncoproteins is a potentially effective therapeutic strategy.

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical trial updates and the company's efforts to reduce costs.
• Employees may be impacted by the company's financial performance and the progress of its clinical programs.
• Patients may benefit from the development of new treatment options for HPV-related cancers.
• Investors may be interested in the company's potential for future growth and profitability.

Next Steps

• The company expects an FDA clearance decision for the updated VERSATILE-003 trial design by mid-December 2024.
• Site activation for the VERSATILE-003 trial is expected to begin in the first quarter of 2025.
• The company is exploring the next steps in the development of Versamune HPV for cervical cancer.
• The company anticipates multiple data readouts from NCI Phase 2 studies of PDS01ADC.

Key Dates

Keywords

PDS Biotechnology, Versamune HPV, Immunotherapy, HNSCC, Cervical Cancer, Clinical Trial, Phase 3, FDA, Pembrolizumab, Financial Results